Olsalazine

The miscellaneous GI drugs include bismuth subsalicylate, mesalamine, misoprostol, olsalazine, sucralfate, and sulfasalazine... 

Bismudi subsalicylate is used in combination witii otiier dru > to treat gastric and duodenal ulcers caused by H. pylori bacteria Mesalamine is used in the treatment of chronic inflammatoiy bowel disease Misoprostol is used to prevent gastric ulcers in those taking aspirin or nonsteroidal anti-inflammatory dragp in high doses for a prolonged time Olsalazine is used in the treatment of ulcerative colitis in those allergic to sulfasalazine. Sulfasalazine is used in the treatment of Crohn s disease and ulcerative colitis. Sucralfate is used in the treatment of duodenal ulcer. 

Oral administration of mesalamine may cause abdominal pain, nausea, headache dizziness, fever, and weakness. The adverse reactions associated witii rectal administration are less than those seen witii oral administration, but headache abdominal discomfort, flu-like syndrome, and weakness may still occur. Olsalazine administration may result in diarrhea, abdominal discomfort, and nausea Sulfasalazine is a sulfonamide witii adverse reactions the same as for the sulfonamide drugs (see Chap. 6). 

Misoprostol is used cautiously in women of childbearing age. Mesalamine, olsalazine, sucralfate, and sulfasalazine are Pregnancy Category B drugs all are used with caution during pregnancy (safety has not been established) and lactation. 

Olsalazine—If diarrhea develops, contact the pri-rnary health care provider as soon as possible ... 

C Hs03 119-36-8) see Acenocoumarol Olsalazine sodium Salbutainol Salicylamide 2-methyl-L-serine... 

Aspirin, sodium salicylate, choline magnesium trisalicylate, salsalate, diflunisal, salicylsalicylic acid, sulfasalazine, olsalazine... 

Hixson, L., Trujillo, A., Hansen, K., Ritchie, J. and Earnest, D. (1992). Effect of oral olsalazine "sodium and parenteral... 

Newer mesalamine products utilize non-sulfapyridine methods for drug delivery. Olsalazine uses two mesalamine molecules linked together, while balsalazide uses the inert carrier molecule 4-aminobenzoyl-P-alanine. Both drugs use a diazo bond similar to sulfasalazine. Other mesalamine formulations are pH-dependent formulations that release mesalamine at various points throughout the GI tract. 

The use of non-sulfapyridine-based aminosalicylates has led to greater tolerability. Although the adverse effects are similar to those of sulfasalazine, they occur at a much lower rate. Olsalazine, in particular, is associated with a higher incidence of secretory diarrhea. These agents can also be used safely in patients with a reported sulfonamide allergy. 

Olsalazine Dipentum Dimer of 5-aminosalicylic acid 1.5-3 g Colon... 

Oral mesalamine derivatives may impose a lower frequency of adverse effects compared with sulfasalazine. Up to 90% of patients who are intolerant to sulfasalazine will tolerate oral mesalamine derivatives. Olsalazine may cause watery diarrhea in up to 25% of patients. 

Olanzapine (Zyprexa) Antipsychotic Olopatadine (Patanol) Antihistamine Olsalazine (Dipentum) Ulcerative colitis Omeprazole (Prilosec) Proton pump inhibitor... 

Nortriptyline 53 Notvasc 15 Notvir 60 Na/din 79 Nubain 50 Nystatin 53, 77 Octreotide 53 Ofloxadn 53 Ogen 33 Olopatadine 53 Olsalazine 53... 

Ofloxacin, 141,142,144,145 Ofomine, 102 Olsalazine, 42 Olvanil, 35 Omeprazole, 133 Oral antidiabetic agent, 3 Oral contraceptives, 66, 68 Orange crush, 62 Organoplatinum complexes, 15 Oxagrelate, 151,152 Oxaprotiline, 63 Oxendolone, 66 Oximonam, 195... 

Pharmacology Olsalazine sodium is a sodium salt of a salicylate compound that is effectively bioconverted to 5-aminosalicylic acid (mesalamine 5-ASA), which has anti-inflammatory activity in ulcerative colitis. Approximately 98% to 99% of an oral dose will reach the colon, where each molecule is rapidly converted into 2 molecules of 5-ASA by colonic bacteria. The liberated 5-ASA is absorbed slowly, resulting in very high local concentrations in the colon. 

Pharmacokinetics After oral administration approximately 2.4% of a single 1 g oral dose is absorbed. Maximum serum concentrations appear after approximately 1 hour, and are low even after a single 1 g dose. Olsalazine has a very short serum half-life of approximately 0.9 hours and is greater than 99% bound to plasma proteins. Urinary recovery is less than 1%. Total oral olsalazine recovery ranges from 90% to 97%. 

Renal abnormalities Renal abnormalities were not reported in clinical trials with olsalazine however, the possibility of renal tubular damage caused by absorbed mesalamine or its n-acetylated metabolite must be kept in mind, particularly in pre-existing renal disease. 

---